Novo Nordisk set to roll out 7.2 mg Wegovy injection
Novo Nordisk is set to roll out a stronger 7.2 mg dose of Wegovy, its popular weight-loss shot. This new option is for people aiming to lose even more weight.
Early results show some users could drop up to 28% of their body weight, compared to the average 17% weight loss seen in trials.
Wegovy 7.2 mg spares muscle
The cool part? Most of the weight lost with this dose comes from fat, not muscle, so people keep their strength and mobility.
Novo Nordisk says flexible dosing matters because everyone's needs are different.
The higher dose is launching in Europe and the UK and Novo Nordisk also plans to pursue India, even as the company faces tough competition from generic versions there.
Despite that, it is optimistic since semaglutide (the main ingredient) is seeing big demand for both heart health and weight management.